The purpose of this research is to study whether adding an FDA approved medication called aprepitant (a medication given to patients like you to reduce or eliminate nausea and vomiting) to the usual treatment to prevent nausea and vomiting given to patients during knee replacement surgery helps more patients go home on the same day of surgery (before midnight) by eliminating nausea and vomiting.

Start Date01 Jul 2026

Sponsor / Collaborator

Endeavor Health

[+1]

NCT07371728

/ Not yet recruitingPhase 4IIT

Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery: A Pilot Randomized-Controlled Trial

This project is being carried out to study the use of a medication to reduce nausea and vomiting after ear surgery.

Start Date01 Jun 2026

Sponsor / Collaborator

Mortimer B. Davis Jewish General Hospital Foundation

ChiCTR2600124681

/ Not yet recruitingNot Applicable

A Randomized Controlled Trial of Aprepitant for the Prevention of Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgery.

Start Date20 Apr 2026

Sponsor / Collaborator

Beijing Hospital of the Ministry of Health

100 Clinical Results associated with Aprepitant

100 Translational Medicine associated with Aprepitant

100 Patents (Medical) associated with Aprepitant

1,537

Literatures (Medical) associated with Aprepitant

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Retraction Note: The effect of substance P and its specific antagonist (aprepitant) on the expression of MMP-2, MMP-9, VEGF, and VEGFR in ovarian cancer cells

Article

Author: Momen Razmgah, Maryam ; Isaac Hashemy, Seyed ; Javid, Hossein ; Afshari, Amir-R ; Ghahremanloo, Atefeh ; AlAlikhan, Abbas

01 Sep 2026·CANCER LETTERS

Repurposing the Neurokinin-1 receptor antagonist Aprepitant to eradicate relapsed/refractory acute lymphoblastic leukemia via mitochondria-driven necroptosis

Article

Author: Wang, Xi ; Ma, Junjie ; Wang, Huafeng ; Pan, Hanling ; Zhu, Jiayi ; Shao, Gang ; Cheng, Xurui ; Wu, Hongzhang ; Zhuo, Nanfang ; Fu, Caiyun ; Tong, Xiangmin ; Hong, Xiangyu ; Xiao, Ruitao ; Li, Jianhu

The prognosis for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) remains dismal due to intrinsic and acquired chemoresistance, highlighting an urgent need for novel therapeutic strategies. The neurokinin-1 receptor (NK-1R) represents an emerging oncological target, yet its role and therapeutic potential in ALL are incompletely understood. Here, we identify the NK-1R as a robust therapeutic target that is significantly overexpressed in both primary and R/R ALL. The FDA-approved NK-1R antagonist Aprepitant potently inhibited the proliferation of ALL cells and overcame resistance to chemotherapeutic drugs in both patient-derived samples and doxorubicin-resistant cell lines. Mechanistically, Aprepitant triggered a novel mitochondria-driven necroptotic pathway, distinct from the apoptosis induced by NK-1R blockade in other cancers we previously reported [5,6]. This pathway is initiated by endoplasmic reticulum (ER) calcium release and ER stress, leading to mitochondrial calcium overload, reactive oxygen species (ROS) burst, and subsequent mitochondrial fission, which ultimately activates the phosphorylation of the core necroptotic effectors RIP1, RIP3, and MLKL. Pharmacological inhibition or genetic knockdown of key regulators of necroptosis, ER stress, or mitochondrial ROS significantly attenuated Aprepitant-induced cell death. Importantly, Aprepitant exhibited significant in vivo anti-leukemic efficacy in a xenograft mouse model. Our findings not only elucidate a unique, mitochondria-mediated necroptotic mechanism engaged by NK-1R inhibition but also provide a compelling rationale for the immediate clinical repurposing of Aprepitant as a targeted therapy for R/R ALL.

01 Aug 2026·LIFE SCIENCES

Ameliorative impact of aprepitant on cisplatin testicular toxicity: Dual regulation of PI3K/AKT pro-survival signaling and Bax/cytochrome c/caspase-3 apoptotic signaling

Article

Author: Azouz, Amany A ; Sharkawi, Souty Mouner Zaky ; Attya, Mina Ezzat ; Khalifa, Yassmen Mohamed Montaser A ; Mohamed, Taha Bakry

AIM:

Cisplatin is a powerful antineoplastic agent utilized for the management of several cancers. Due to its significant deleterious impact on the testis, manifested as long-term infertility and irreversible azoospermia in 50% of individuals, its clinical application is markedly restricted. Therefore, this study focused on the investigation of aprepitant's potential effectiveness against cisplatin-induced testicular injury due to its previously reported efficacy in modulation of inflammatory, pro-survival, and apoptotic signaling.

MAIN METHODS:

In a 10-day experimental protocol, male Wistar rats were assigned to five groups: normal control, aprepitant (20 mg/kg), cisplatin (10 mg/kg, 5^th day-only), aprepitant (10 mg/kg) + cisplatin, and aprepitant (20 mg/kg) + cisplatin, then sacrificed on day 11. Sperm quality and testosterone level were evaluated, along with biochemical, immunohistochemical, and histopathological analysis of the testicular tissue.

KEY FINDINGS:

Cisplatin administration notably diminished sperm viability, count, morphology, and increased abnormalities, alongside the decline in serum testosterone level. Furthermore, cisplatin upregulated nuclear factor-kappa B p65 (NF-κB p65), while downregulating phosphorylated-phosphatidylinositol-3-kinase (p-PI3K), and phosphorylated protein kinase B (p-AKT) protein expressions in testicular tissue sections. That in turn enhanced the transcription of interleukin-6 (IL-6), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) pro-inflammatory cytokines, aggravated oxidant/antioxidant imbalance, triggered apoptosis via Bax/cytochrome c/caspase-3 intrinsic pathway, while suppressing the antiapoptotic Bcl-2 protein. In contrast, aprepitant treatment guarded against these alterations in a dose-dependent manner.

SIGNIFICANCE:

Aprepitant exhibits efficient protection against cisplatin-induced testicular toxicity that could be attributed to its inhibitory influence on Bax/cytochrome c/cleaved caspase-3 apoptotic signaling, with simultaneous enhancement of PI3K/AKT pro-survival signaling.

News (Medical) associated with Aprepitant

25 Aug 2026

·www.prnewswire.com

Fosun Pharma Announces 2026 Interim Results

Globalization Accelerates Value Realization of Innovative Drugs SHANGHAI, Aug. 25, 2026 /PRNewswire/ -- On August 25, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its interim results for 2026. In the first half of 2026 ("the Reporting Period", or 1H2026), the Company recorded revenue of RMB 20.442 billion, a year-on-year increase of 4.75%, or 7.17% at constant exchange rates. Profit attributable to shareholders of the listed company, net of non-recurring gains and losses, stood at RMB 1.144 billion, up 19.09% year-on-year. Profit growth outpaced revenue growth, reflecting sustained improvement in earnings quality. Net cash generated from operating activities reached RMB 2.424 billion, rising 13.59% year-on-year. Innovation and globalization stand as the dual core engines driving business performance. Revenue from Innovative Drugs hit RMB 4.911 billion, representing a 13.84% year-on-year increase and accounting for 33.21% of pharmaceutical segment revenue, 2.17 percentage points higher than the same period last year. Business revenue from regions outside Chinese mainland and other countries totaled RMB 6.379 billion, growing 16.45% year-on-year and making up 31.21% of total revenue, a year-on-year uplift of 3.14 percentage points. The Group's revenue mix continues to improve. Focusing on Core Therapeutic Areas and Accelerating Clinical Translation of Innovative Drugs Guided by clinical-value-driven innovation, Fosun Pharma prioritises three core therapeutic areas: oncology, immunology and inflammation, and neurodegenerative diseases. It also expands into CVRM (cardiovascular, renal and metabolic), anti-infectives, rare diseases and other segments. Leveraging an open-innovation framework that combines in-house R&D, two-way licensing and fund-incubation models, the Company accelerates clinical translation and pushes forward its innovation-led transformation. In 1H2026, Fosun Pharma's total R&D investment amounted to RMB 3.247 billion, up 25.66% year-on-year. Among this, R&D investment related to Innovative Drugs accounted for 81.61% of total R&D investment, primarily directed towards pipelines such as HLX43, HLX22, GR1803, FXR0906, as well as next-generation small molecule drugs, radiopharmaceuticals, and other cutting-edge technology platforms. During the reporting period, Fosun Pharma's Innovative Drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7 Innovative Drugs were approved for launch both domestically and overseas. In solid tumor areas including lung cancer, breast cancer, and gastrointestinal tumors, the Company has established differentiated competitive advantages through multi-product synergy and global commercialization. Han Li Kang (Rituximab), Han Qu You (trastuzumab), and Akynzeo® continue to maintain leading positions in their respective market segments, consistently contributing stable cash flow. During H1 2026, Han Si Zhuang (Serplulimab) gained approval in China for the perioperative treatment of gastric cancer, filling a global unmet clinical need. In the EU, it obtained three additional first-line approvals for squamous non-small-cell lung cancer, esophageal squamous-cell carcinoma and non-squamous non-small-cell lung cancer. To date, serplulimab has been launched in approximately 50 countries and regions worldwide and is reimbursed under national health-insurance or public-reimbursement schemes in 12 markets including the United Kingdom, Germany, Italy, Spain and Sweden. Han Bei You (Pertuzumab) received successive marketing approvals in the EU and China. It works in synergy with breast-cancer portfolio assets including Han Qu You, Han Nai Jia and Fu Tuo Ning to drive commercial uptake. Fu Mai Ning (luvometinib tablets) secured a new indication for pediatric and adolescent patients aged two years and older with relapsed/refractory Langerhans-cell histiocytosis (LCH) following systemic therapy, addressing an unmet clinical need in China. With regulatory applications accepted for multiple innovative drugs and international multi-center clinical trials for key pipelines moving forward efficiently, Fosun Pharma continues to fuel its long-term commercial growth. - The NDA for SAF-189 (foritinib succinate capsules), an ALK inhibitor for non-small-cell lung cancer, has been accepted by the NMPA. - The NDA of Fu Mai Ning for adult patients with symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1 (NF1) has been accepted and granted priority review by the NMPA. - The NDA for Velinotamig (GR1803), a BCMA × CD3 bispecific antibody for multiple myeloma, has been accepted. Lead pipeline candidates HLX43 and HLX22 are progressing in international multi-center trials across China, the US, Europe, Australia, Japan and other geographies. As a potential best-in-class pan-tumor PD-L1-targeting ADC, HLX43 has demonstrated promising preliminary clinical efficacy featuring high potency and favorable safety profiles across multiple solid tumors types including non-small-cell lung cancer. In the immunology and inflammation field, the Company strengthened its in-house R&D while continuously enriching its pipeline through BD collaborations, obtaining the rights to develop, manufacture, and commercialize roconkibart (anti-IL-17A monoclonal antibody) in Chinese mainland, Hong Kong SAR, Macau SAR, and Taiwan region. The complement inhibitor FXS6837 for the treatment of IgA nephropathy and other glomerular diseases associated with complement dysregulation initiated Phase 2b clinical trials in Chinese mainland. The DPP1 inhibitor FXS7553 is in Phase 2 clinical stage in Chinese mainland for two indications: non-cystic fibrosis bronchiectasis and COPD. In the neurodegenerative diseases field, the integrated diagnosis and treatment layout continues to strengthen. The post-marketing confirmatory clinical trial for Sodium Oligomannate Capsules in Chinese mainland is progressing steadily; as of July 31, 2026, cumulative enrollment exceeded 1,000 cases, reaching over 50% of the planned enrollment target. HT001, an investigational drug for Parkinson's disease, has initiated Phase 1 clinical trials in Australia. Parallel work is underway on the clinical deployment of magnetic-resonance-guided focused-ultrasound therapy and the R&D of companion diagnostic reagents. Rooted in evidence-based medicine, Fosun Pharma presented three oral abstracts at the 2026 ASCO Annual Meeting, including the Phase 3 study of Fu Mai Ning in adult NF1 patients, the Phase 3 study of serplulimab injection in the perioperative setting for gastric cancer, and the clinical study of HLX43 in non-small cell lung cancer. 10 studies were selected for poster presentations at the 2026 ASCO Annual Meeting, including data from two Phase 3 studies of Fu Tuo Ning and a study of HLX43 in nasopharyngeal carcinoma. The Company continues to deliver high-quality clinical outcomes in top-tier global journals such as The Lancet and Nature Medicine, as well as at global industry academic conferences, providing solid academic support for international registration and commercial expansion of its products. Deep Globalization: Global Capabilities Accelerate Value Delivery of Innovation Among China's early-movers in global pharmaceutical expansion, Fosun Pharma is evolving from mere product exports toward system - level global deployment. It strengthens cross-border capabilities across R&D, regulatory affairs, manufacturing and commercialization to maximize the global value of its innovative assets. In terms of out-licensing, Shanghai Henlius, a subsidiary of Fosun Pharma, has entered strategic partnerships with Eisai and Abbott for serplulimab. Eisai obtains development, manufacturing and exclusive commercialization rights for Japan and agreed territories. Abbott receives exclusive commercial-license rights covering 42 countries and regions across Asia, the Middle East, Africa and Eastern Europe. These collaborations accelerate global roll-out of home-grown innovations for patients worldwide. In terms of in-licensing, Fosun Pharma entered into a global exclusive option agreement with AriBio for AR1001, an investigational drug for Alzheimer's disease. Building on the existing rights in China and Southeast Asia, Fosun Pharma is entitled to further expand its right to global core markets including the US, Europe, and Japan, with the Company serving as the marketing authorization holder for the product in the corresponding territories. The international multi-center Phase 3 clinical trial of AR1001 for the treatment of early Alzheimer's disease has completed the last patient's last visit, with top-line results to be announced within 2026. Drawing on years of global GMP-compliant manufacturing experience, Fosun Pharma presses ahead with its internationalization drive. Its biotech manufacturing site supplies products routinely to global markets including China, Europe, Canada, Latin America, Southeast Asia and India. As of period-end, installed biologic capacity totaled 84,000 liters, of which 48,000 liters are commercially operational. Fosun Pharma's subsidiary Gland Pharma, as the first injectable manufacturer in India to receive U.S. FDA approval, possesses one-stop development and manufacturing capabilities for complex dosage forms including vials, lyophilized products, ampoules, and pre-filled syringes. Gland Pharma recently entered into a strategic supply agreement with a global leading pharmaceutical company for 55 SKUs of sterile injectable, further validating its technological expertise and customer stickiness in the high-barrier complex formulation segment. This platform also provides Fosun Pharma with a unique strategic resource for its globalization layout, creating a differentiated competitive advantage in the process of going global. Bolstered by its innovation and globalization strengths, Fosun Pharma keeps elevating its industry standing and has achieved an MSCI ESG rating upgrade to AAA[1]. Domestically, it has ranked among the top 10 of MIIT's China Top 100 Pharmaceutical Enterprises for eight consecutive years. Globally, its innovative-pipeline scale places it within the world's top tier, ranking top 20 in Citeline's Global Top 25 Pipeline Scale Pharmaceutical Companies. "Amidst challenging industry dynamics, Fosun Pharma responded to external uncertainties with strategic focus, achieving steady revenue growth." Chen Yuqing, Chairman of Fosun Pharma, said, "We stay firmly committed to innovation and globalization. Concentrating on oncology, immuno-inflammation and neurodegenerative diseases, we leverage our global footprint and two-way BD synergies to build stronger commercial capabilities. Amid global-expansion opportunities for China's innovative drugs, we take a long-term view and advance resolutely toward high-quality development." - END - About Fosun Pharma Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. With the mission of Better Health for Families Worldwide, we focus on developing innovative medicines, medical technologies and diagnostics as well as delivering healthcare services. Through our business partner Sinopharm Group, we have also established pharmaceutical distribution network, built a comprehensive pharmaceutical and healthcare ecosystem. Fosun Pharma is dedicated to innovation and globalization. The company has established a global R&D innovation system targeting at unmet medical needs. Our strategic focus is on key therapeutic areas including oncology, immunology and inflammation, neurodegenerative diseases, and selected cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. These efforts have strengthened our early-stage innovative portfolios and accelerated the transformation of scientific discoveries to drug development. Our innovative products are now available in more than 90 countries and regions worldwide, including major markets across China, the United States, Europe, Africa, India and Southeast Asia. Looking ahead, guided by the strategy of "Innovation Driven, Deep Globalization, and AI Embracement", Fosun Pharma remains committed to its core values: Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership. We strive to become a leading global healthcare innovation integrator, ensuring that the benefits of medical innovation reach more patients worldwide, and contribute to safeguarding human health. For more information about the Group, please visit the company website: SOURCE Fosun Pharma 21% more press release views with Request a Demo

Phase 1Drug ApprovalLicense out/inPhase 2Phase 3

22 Jul 2026

·www.ventouxbio.com

Encouraging Progress In Our Dupuytren’s Research

Ventoux Bio July 22, 2026 Dupuytren's Information, Events We have now studied VEN-201 in human Dupuytren’s tissue from several individual donors, and the early results are genuinely encouraging. Across these samples, VEN-201 has shown consistent signs of acting on the biological processes that drive the disease, exactly the direction we hoped to see. What gives us particular confidence is that consistency. Seeing the same direction of effect across tissue from different people, despite the natural variation from one person to the next, is an important early signal that we may be engaging the true drivers of the disease rather than seeing a one-off result. It is still early, and there is real work ahead before this reaches patients, but this is the kind of human-anchored evidence that strengthens our conviction and helps open doors with research and funding partners. Out of respect for the scientific process, we are sharing these findings at a high level for now, with more detail to follow as the work matures. Our focus now is to build on these findings: studying additional donor tissue to further test what we are seeing, deepening our understanding of how VEN-201 works, and advancing the preparation needed to move toward a first clinical study. Each of these steps brings us closer to testing VEN-201 in patients, and each one depends on continued support. This is the question closest to my own heart and the one I receive the most from fellow patients. Our current estimate is roughly 18 months to a first clinical study, and reaching that milestone depends heavily on funding. Here is the honest part. Dupuytren’s affects millions of people, yet it has long been underfunded for how common and life-altering it is, and today’s climate is especially hard for early-stage research. Many investors now wait to commit until a therapy is already being tested in humans, which leaves promising pre-clinical programs like ours in a real gap. We are pushing hard to reach that in-human stage, and it is truly within sight. That final stretch is where community support matters most. Any and all help, whether you run with me, donate, or invest, moves us from promising science into the clinic and closer to the day patients can join a study. There are three ways to be part of this, whichever fits you best: Run with Me. This October I am running the 25k at the Lake Hodges Trail Festival in San Diego and I would love for you to join our team and run with me. Our team name is the Dupuytren’s & Ledderhose Run Collective, more info below. Donate. If you would rather cheer from the sidelines (near or far), every dollar donated does directly to our Dupuytren’s research at Ventoux Biosciences. Please donate and / or share with fellow patients impacted by this disease. Invest. We have a crowdfunding campaign now open and anyone can invest. WeFunder is a regulated investment crowdfunding platform where everyday investors can invest in Ventoux and receive equity, an ownership stake in the company, rather than making a donation. Investment minimum is $100. Company News Dupuytren's Information Events Johnny Randel is a senior finance executive who has more than 30 years of experience in financial institutions including over 17 in private equity. Mr. Randel recently retired as the Chief Financial Officer (“CFO”) of StepStone Group. Inc (Nasdaq: STEP), a global private markets specialist firm delivering tailored investment solutions, advisory services, and impactful, data-driven insights to the world’s investors with $678B of capital responsibility. Mr. Randel spent over 13 years leading the corporate and investment finance and accounting teams and was the CFO for the lead up and execution of the company’s initial public offering in 2020. Previously, Mr. Randel held the role of Chief Financial Officer and Chief Operating Officer at Citigroup Private Equity overseeing financial and operational activities for the company and its coinvestment, mezzanine, and fund of fund investment programs. Mr. Randel also held a previous role as Assistant Treasurer within Citigroup Inc.’s Treasury department where he managed rating agency relationships and fixed income client relations. Mr. Randel also held various finance roles supporting corporate finance and strategy over the course of his career. Mr. Randel received his B.G.S. from the University of Kansas and MBA from the University of Southern California. Mr. Cravets is an industry leader in biostatistics with extensive experience in program design and analysis. He currently serves as the Senior Vice President of Biometrics at Gossamer Bio. Prior to joining Gossamer Bio, Mr. Cravets was Vice President of Biometrics at Heron Therapeutics Inc. from 2016 to 2018, where he played a key role in the late-stage development programs for Zynrelef for the treatment post-surgical pain and Cinvanti for the prevention of chemotherapy induced nausea and vomiting. Before joining Heron, Mr. Cravets was Executive Director of Biometrics at Receptos Inc. from 2014 to 2016, where he built the biostatistics and data management functions while contributing to mid- and late-stage development programs for ozanimod (Zeposia) in multiple sclerosis (MS) and inflammatory bowel diseases (IBD). Before joining Receptos, Mr. Cravets was the head of biostatistics at Ardea Biosciences from 2011-2014, building the biostatistics function while also making significant contributions to the designs and analyses of late-stage studies of lesinurad (Zurampic) for the treatment of gout. From 2003-2011 Mr. Cravets served in roles of increasing responsibility in the biostatistics group at Biogen Idec Inc., contributing to the successful regulatory approvals of rituximab (Rituxan) in both rheumatoid arthritis (RA) and chronic lymphocytic leukemia (CLL). From 1996 to 2003, Mr. Cravets was in the biostatistics group at Amgen, Inc., working on multiple products across various neurology, rheumatology, cardiovascular, and bone disease indications. Mr. Cravets began his career in the pharmaceutical products division of Abbott Laboratories in 1994 after completing his master’s degree in statistics at the University of Michigan and his bachelor’s degree in mathematics at UCLA. Dr. Satish is a trained biotechnologist with several years of experience in cell and molecular biology. Dr. Satish’s interest has been in skin research with a special focus on skin inflammation, infection, and fibrosis. The other arm of Dr. Satish’s research has been to study the molecular determinants of palmar fascial disease, Dupuytren’s contracture. Her long-term interest has been to develop therapeutic agents to help alleviate the pain and distress of patients with Dupuytren’s. Her studies on Dupuytren’s disease were funded by a private donor, which moved the research forward to study this disease in an animal model, which was not feasible earlier. Dr. Satish’s research on Dupuytren has identified small molecules that can be used as a target to intervene with the progression and development of the disease. Dr. Satish received her Ph.D. from a prestigious institute in India and did her post-doctoral training at the University of Pittsburgh. Currently, Dr. Satish serves as a faculty at the Division of Asthma Research, Cincinnati Children’s Hospital; named as the top hospital in the US. At Cincinnati Children’s, Dr. Satish researches Atopic Dermatitis, a chronic inflammatory skin disease affecting children and adults. Dr. Satish has published over 50 articles in peer-reviewed journals, review articles and book chapters. Dr. Denkler is an accomplished, board certified plastic surgeon with expertise in aesthetic and reconstructive surgery. Dr. Denkler is a clinical professor of plastic surgery at UCSF and has a private practice in Marin County. He is internationally renowned for his use of multiple approaches in treating the debilitating and disabling effects of palmar fibromatosis (Dupuytren disease). Dr. Denkler is an expert in needle aponeurotomy (NA), a minimally invasive procedure that uses subcutaneous needles to release the contracture as well as use of subcutaneous injection of collagenase. He has treated over 10,000 Dupuytren’s fingers, authored >35 publications and book chapters, presented internationally and domestically and is often cited for expert opinion in national and international news discussing Dupuytren’s. HIs pioneering investigational work documenting the safety of epinephrine with local anesthesia contributed to the origination of “wide-awake hand surgery”. Dr. Denkler trained at prestigious medical institutions in the United States and Europe. He attended Baylor College of Medicine in Houston, Texas, followed by residency training in plastic and reconstructive surgery with the Cronin, Bauer, and Biggs group, also in Houston. Additionally, Dr. Denkler completed a hand surgery fellowship with Dr. Eugene Kilgore in San Francisco and one year of fellowship training in craniofacial surgery with Dr. Paul Tessier in Paris, France. Daiva Bajorunas MD is an endocrinologist with more than 25 years of experience in the biopharmaceutical industry. She has a strong interest in advancing therapeutic options for conditions of significant unmet medical need. For the past decade, Daiva has been engaged as a consultant to the pharmaceutical industry, currently as Founder and Principal, DBMD Consulting, and previously as Chief Medical Officer / Chief Scientific Officer for Vault Bioventures. She has provided her expertise to enhance large, mid-size and small pharmaceutical company product development, clinical/regulatory, and life cycle strategies for both drugs and devices, including oral, transdermal, injectable and inhalative delivery systems, working across multiple therapeutic areas and geographies. She has considerable experience chairing Data Safety Monitoring Boards. In the past she held various R&D positions of increasing responsibility at Rhone-Poulenc Rorer, BMS, Aventis (acquired by Sanofi), and Kos Pharmaceuticals (acquired by Abbott). Before she joined industry, she held academic appointments at Memorial Sloan-Kettering Cancer Center and Cornell University Medical College (CUMC), and was Director of Clinical Care, Endocrinology Service, Memorial Hospital (MH), New York, NY. Daiva received her MD degree at the University of Michigan Medical School, did her residency training at St. Vincent’s Hospital & Medical Center in NY, her metabolism fellowship at Stanford University Medical Center, CA and her endocrinology fellowship at MH/CUMC, NY.

Executive Change

07 May 2026

·www.prnewswire.com

Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients

Regulatory Clearance in Spain Advances Randomized, Placebo-Controlled Study; Patients Show Meaningful Reductions in EGFR-Inhibitor Skin Toxicities with No Treatment Disruptions May 5, 2026 -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced that it has secured regulatory authorization in Spain for its Phase 2a CLEER Trial of HT-001, while concurrently reporting encouraging interim clinical results demonstrating meaningful efficacy and safety in cancer patients experiencing EGFR inhibitor-associated skin toxicities. The authorization supports the continued advancement of Hoth's randomized, placebo-controlled, dose-ranging Phase 2a study evaluating HT-001 for the treatment of dermatologic toxicities associated with epidermal growth factor receptor (EGFR) inhibitor therapies. Preliminary data from the ongoing study indicate: Patients achieved the primary efficacy endpoint, with rash severity reduced to clinically manageable levels (ARIGA ≤1) by Week 6 Over 65% of patients reported meaningful reductions in pain and itching Zero patients required dose reduction or discontinuation of their underlying EGFR inhibitor cancer therapy Favorable safety profile, with no treatment-limiting adverse events observed These findings suggest that HT-001 may enable patients to remain on life-saving cancer therapies longer, addressing a major limitation of current oncology treatment regimens. "Regulatory advancement paired with strong clinical signals has helped open up a new avenue for patients in Spain," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "Securing European authorization while demonstrating meaningful patient benefit reinforces our belief that HT-001 has the potential to become a critical supportive care therapy in oncology." The Spain authorization marks an important step in Hoth's European strategy and supports continued trial execution and expansion across additional regions. The CLEER Trial (Chemotherapy Longevity by Evading EGFR Inhibitor Reactions) is a Phase 2a randomized, placebo-controlled, parallel, dose-ranging study evaluating HT-001 in patients experiencing EGFR inhibitor-related dermatologic toxicities. HT-001 is a novel topical therapeutic designed to target inflammatory pathways associated with cancer therapy-induced skin toxicities, with the goal of improving tolerability and enabling uninterrupted treatment. Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. The content above comes from the network. if any infringement, please contact us to modify.

Clinical Result

100 Deals associated with Aprepitant

External Link

KEGG	Wiki	ATC	Drug Bank
D02968	Aprepitant	A04AD12	DB00673

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Postoperative Nausea and Vomiting	European Union	Merck Sharp & Dohme BV	11 Nov 2003
Postoperative Nausea and Vomiting	Iceland	Merck Sharp & Dohme BV	11 Nov 2003
Postoperative Nausea and Vomiting	Liechtenstein	Merck Sharp & Dohme BV	11 Nov 2003
Postoperative Nausea and Vomiting	Norway	Merck Sharp & Dohme BV	11 Nov 2003
Chemotherapy-induced nausea and vomiting	United States	Merck Sharp & Dohme LLC	26 Mar 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Germ Cell and Embryonal Neoplasms	Phase 3	United States	Merck Sharp & Dohme LLC	01 Dec 2007
Breast Cancer	Phase 3	-	Merck Sharp & Dohme Corp.	01 Dec 2002
Nausea	Phase 3	-	Merck Sharp & Dohme Corp.	01 Dec 2002
Vomiting	Phase 3	-	Merck Sharp & Dohme Corp.	01 Dec 2002
Depressive Disorder, Major	Phase 3	-	Merck Sharp & Dohme Corp.	01 Sep 2001
Acneiform Eruptions	Phase 2	United States	ICON Clinical Research, Inc.	19 Jul 2023
Acneiform Eruptions	Phase 2	Poland	ICON Clinical Research, Inc.	19 Jul 2023
Acneiform Eruptions	Phase 2	Spain	ICON Clinical Research, Inc.	19 Jul 2023
Asteatosis cutis	Phase 2	United States	ICON Clinical Research, Inc.	19 Jul 2023
Asteatosis cutis	Phase 2	Poland	ICON Clinical Research, Inc.	19 Jul 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


DDW2026	Not Applicable	Gastroparesis \| Diabetic Gastroparesis	464	NK-1 Receptor Antagonists	jwzsdmlomd(ksajcvmdma) = okagbpkwrr mzexqerrjf (thmbhijmop )	Positive	02 May 2026
				Placebo	jwzsdmlomd(ksajcvmdma) = kanzpobhpf mzexqerrjf (thmbhijmop )
ASH2025	Not Applicable	Acute Myeloid Leukemia	204	Extended aprepitant	auazdogubt(helxlqnlwc) = Adverse effect profile including febrile neutropenia or its complications, also did not differ between the two groups. owjlvzirfx (vlqeszsujy ) View more	Negative	06 Dec 2025
				Standard aprepitant
PRNewswire Manual	Not Applicable	Drug Eruptions	1	HT-001	zlbhcnlqix(pbpybpigvw) = After just one week of applying HT-001 2% cream twice daily, the patient experienced full symptom and lesion resolution, with no recurrence of lesions in the following three weeks. lvgluhstco (xnskulfzar )	Positive	05 Mar 2025
NCT05639933 (CLEER-001, Biospace) Manual	Phase 2	Skin Diseases	-	HT-001	yvrxlzwoqp(cpzvzocysj) = lfqmauxrji lvfwqgsxxi (eyxnpgvnng ) Met View more	Positive	07 Jan 2025
ESMO_ASIA2024	Not Applicable	-	150	Fosnetupitant + Palonosetron (FP)	zshiycrwnl(knjeizkeqo) = thwysvtvop xonyrzmhqf (kjqvyjdhoc )	Positive	07 Dec 2024
				Oral Aprepitant + Palonosetron (AP)	zshiycrwnl(knjeizkeqo) = mwnmciuiyu xonyrzmhqf (kjqvyjdhoc )
NCT03435003 (CTgov)	Phase 4	Postoperative Nausea and Vomiting \| Vomiting	83	dexmedetomidine+Total intravenous anesthesia+Fentanyl+scopolamine transdermal+Compazine+sugammadex+Reglan+Propofol+Dexamethasone+Ondansetron+Aprepitant 80 mg Oral Capsule (Intervention Arm)	jbujrhpxzk = ombjmxngsz tiqsnnhqbn (qixruljvnf, sqwvbivxux - bjazbwxbkc) View more	-	14 Feb 2024
				Compazine+sugammadex+Reglan+Sevoflurane+Dexamethasone+desflurane+Ondansetron (Control Arm)	jbujrhpxzk = cfaeuzxgda tiqsnnhqbn (qixruljvnf, qpnuqzhlyq - pncotwjnvt) View more
NCT02939287 (CTgov)	Phase 3	Nausea \| Vomiting	52	Aprepitant (Aprepitant)	rcqizycwpl = gfgshztnkx ixzupvifwm (cidkiqpduu, iquynsnsuy - kysbjxzwjf) View more	-	22 Jan 2024
				Olanzapine (Olanzapine)	rcqizycwpl = rfacbzsulb ixzupvifwm (cidkiqpduu, eyonblocqr - lwyavvvdru) View more
NCT04873284 (Pubmed \| Transl Pediatr)	Phase 3	Chemotherapy-induced nausea and vomiting	108	Intravenous fosaprepitant	ywlezgiyoe(vywshswjiy) = suwymzjdpn cdxrbwndcw (sazzfoivnr ) View more	Positive	01 Jan 2024
				Oral aprepitant	ywlezgiyoe(vywshswjiy) = indnntegbd cdxrbwndcw (sazzfoivnr ) View more
NCT03237611 (CTgov)	Phase 2	Chemotherapy-induced nausea and vomiting	15	Dexamethasone+Ondansetron 16 MG+Aprepitant 125 mg+Fosaprepitant 115 MG	lknlmhhxop = qlmwrqgwsz shkqhzvoce (lhtclpemiy, npdyfhfrek - txsepbcmsn) View more	-	13 Nov 2023
ESMO 12023 \| ESMO 22023 Manual	Phase 2	Breast Cancer	76	Palonosetron+aprepitant+ olanzapine	fvdmpjglud(jjrbmbgtmy) = bzaazgzjjm skrfgresmq (rrgknfgoro, 9.4 - 27.5) View more	Negative	21 Oct 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis